IHS Chemical Week

Regions :: Western Europe :: U.K.

Hikma Acquires Stake in Chinese API Manufacturer

4:45 AM MDT | July 12, 2011 | Deepti Ramesh

Hikma Pharmaceuticals (London) says it has acquired a significant minority interest in Hubei Haosun Pharmaceutical through the subscription of new equity for $5 million. Hubei Haosun, a privately held company that develops and manufactures niche, difficult to make active pharmaceutical ingredients (APIs) with a specialization in oncology APIs, is located in the Gedian Economical Development Zone in Hubei province, China. Hubei Haosun operates a U.S. FDA and European Union approved facility and its product portfolio and development pipeline, which covers a range...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa